Aduro Biotech, which is developing two immunotherapy platforms for pancreatic and other cancers, raised $119 million by offering 7 million shares at $17; the company had originally proposed to sell 5 million shares at a $14 to $16 range before upsizing the deal and raising its expected price to $17 in an amended filing on Tuesday morning. Aduro Biotech will list on the NASDAQ under the symbol ADRO. BofA Merrill Lynch and Leerink Partners acted as joint bookrunners on the deal.
